• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-07-17

  Anlotinib hydrochloride sets a new benchmark for anti-angiogenic and anti-proliferative assays, delivering nanomolar potency and broad kinase selectivity. This practical guide translates recent breakthroughs into actionable protocols and troubleshooting strategies for advanced cancer research.

• Azilsartan (TAK-536): Precision Modulation of RAS–SIRT3 in C

  2026-07-17

  Explore the advanced application of Azilsartan (TAK-536) as a potent AT1 receptor antagonist for dissecting the renin-angiotensin system–SIRT3 axis in reactive astrocytes and microglia. This article uniquely examines how Azilsartan enables next-generation neuroinflammation research and cardiovascular modeling.

• Continuous Rotigotine Delivery: Advances in PD and RLS Thera

  2026-07-16

  This review highlights the development and clinical validation of the rotigotine transdermal system, which enables continuous dopaminergic stimulation for Parkinson’s disease (PD) and restless legs syndrome (RLS). By leveraging sustained D2/D3 receptor agonism, the study demonstrates improved management of both motor and non-motor symptoms in PD, as well as efficacy in RLS, overcoming limitations of pulsatile oral therapies.

• Dabigatran in Translational Coagulation Research: Mechanisti

  2026-07-16

  Explore how Dabigatran delivers unparalleled mechanistic clarity in translational coagulation research and clinical assay development. This article goes beyond standard workflows, offering a deep dive into its biochemical actions, clinical relevance, and reference-based protocol guidance.

• RP3-340N1.2 Knockdown Destabilizes IL-6 mRNA in NSCLC

  2026-07-15

  The referenced study demonstrates that the lncRNA RP3-340N1.2 promotes non-small cell lung cancer (NSCLC) progression by stabilizing IL-6 mRNA and that its knockdown suppresses proliferation and migration by enhancing IL-6 mRNA decay. These findings highlight a novel lncRNA-mediated axis for therapeutic intervention and provide mechanistic insight into transcriptional regulation in NSCLC.

• Forsythoside E: Applied PKM2 Inhibitor Workflows and Trouble

  2026-07-15

  Forsythoside E stands out as a selective pyruvate kinase M2 (PKM2) inhibitor with validated utility in immunometabolic and sepsis-induced liver injury research. This article details refined protocols, advanced applications, and evidence-based troubleshooting strategies that empower researchers to fully leverage Forsythoside E’s mechanistic precision.

• Veratridine in Chamber-Specific Cardiomyocyte Research

  2026-07-14

  Explore how Veratridine, a potent voltage-gated sodium channel opener, is reshaping chamber-specific cardiomyocyte modeling and sodium channel dynamics research. This article delivers unique insights into protocol design and translational applications beyond existing guides.

• ω-Agatoxin IVA TFA: Precision Tools for Synaptic Transmissio

  2026-07-14

  ω-Agatoxin IVA TFA enables selective P/Q-type calcium channel inhibition, unlocking high-resolution synaptic transmission and epilepsy model workflows. Its nanomolar potency and specificity streamline neuroprotection studies, making it an essential tool for neuroscience research.

• METTL14-m6A-lncRNA Axis: Epigenetic Regulation in Ulcerative

  2026-07-13

  This study uncovers how METTL14-mediated m6A RNA methylation modulates inflammation in ulcerative colitis through a lncRNA–miRNA–receptor pathway. The findings provide mechanistic insight into m6A-dependent epigenetic regulation in intestinal inflammation, supporting future research into targeted therapies for inflammatory bowel disease.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Research Work

  2026-07-13

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor designed for research requiring targeted inhibition of KIT, PDGFRα, and PDGFRβ signaling. It is best suited for DMSO-based workflows in cancer, mastocytosis, and inflammatory disease models, but is incompatible with aqueous or ethanol-based protocols and should not be used where broad-spectrum kinase inhibition is required.

• 2-D08 (2’,3’,4’-trihydroxyflavone): Precision Sumoylation In

  2026-07-12

  2-D08 (2’,3’,4’-trihydroxyflavone) is a uniquely selective inhibitor of protein sumoylation, enabling targeted disruption of SUMOylation without off-target effects on ubiquitination. Its application streamlines posttranslational modification studies in cancer and mitochondrial biology, offering researchers a powerful tool for mechanistic dissection and disease modeling.

• Antidepressant Properties of Rotigotine in Preclinical Model

  2026-07-10

  This study rigorously evaluates the antidepressant effects of rotigotine, a dopamine D2/D3 receptor agonist, across multiple validated rodent models of depression. The findings reveal dose-dependent behavioral improvements, supporting rotigotine's relevance for Parkinson's disease research addressing both motor and non-motor symptoms.

• Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Linker Use

  2026-07-09

  Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker designed for targeted antibody-drug conjugate (ADC) synthesis, enabling controlled cytotoxic payload release upon lysosomal cleavage. It is optimized for organic solvent-based workflows and not suitable for aqueous, diagnostic, or therapeutic applications. Researchers should follow best practices for storage, solubilization, and workflow integration to ensure reliable results.

• SmD2 Acetylation Modulates Splicing and PARP Inhibitor Sensi

  2026-07-09

  This study elucidates how acetylation-dependent regulation of the core spliceosome protein SmD2 alters alternative splicing and DNA repair in hepatocellular carcinoma (HCC). The findings reveal that modulating SmD2 stability sensitizes HCC cells to PARP inhibitors, highlighting a novel combinatorial therapeutic strategy for BRCA-proficient tumors.

• Macrophage Mertk Drives Heart Failure via Type I IFN in Pres

  2026-07-08

  The reference study uncovers a mechanistic link between macrophage Mertk-mediated efferocytosis and the exacerbation of pressure overload-induced heart failure through a type I interferon pathway. These findings illuminate the role of Mertk in cardiac remodeling and suggest IFN-β as a critical downstream effector, with implications for targeted research on heart failure pathogenesis.

451 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page